mdCurrent Conference Report: 64th American Academy of Neurology Annual Meeting
Follow-up data out to 24 months for the first oral disease modifying therapy (DMT) licensed for treatment of multiple sclerosis (MS) continues to suggest that the efficacy and safety rivals that of the injectable agents that have been the MS treatment mainstay. The most convincing evidence of sustained activity is being generated by studies with magnetic resonance imaging (MRI) that show protection against new lesions and changes in brain morphology relative to placebo.
Key Point: Long-term follow-up data are increasing for the first oral therapy, fingolimod, to demonstrate a disease modifying effect in multiple sclerosis (MS). So far, despite reports of modest changes in blood pressure and heart rhythms, serious adverse effects remain extremely uncommon.
In 24-month data from the FREEDOMS II study, 0.5 mg and 1.25 mg once daily fingolimod were shown to be protective against relapse, brain atrophy on MRI, and progressive disability sustained relative to placebo, according to data presented at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, United States. Just as important, there were no new...
Log in or register for free to continue reading
Register Now For Free
Already Registered? Log In
indicates a Peer-Reviewed Article
First oral disease modifying therapy for multiple sclerosis challenges injectables in long-term data
In 24-month data from the FREEDOMS II study, 0.5 mg and 1.25 mg once daily fingolimod were shown to be protective against relapse, brain atrophy on MRI, and progressive disability sustained relative to placebo, according to data presented at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, United States. Just as important, there were no new...
Related Articles